Matt McNally, CEO of Outcome Health, shares his thoughts on post-controversy Outcome Health and the overall state of the point-of-care union.
Among the group's members are media agencies that had pulled healthcare ad spend from the POC channel in the wake of a scandal 10 months ago.
After a scandal with one of point of care's biggest players, we examine how the community is living up to its promise of greater transparency.
WPP is set to depart its London headquarters in Farm Street after more than 30 years as it seeks "a more modern and attractive office."
Mohan was previously head of global drug-development communications.
Bayer shares fall after Monsanto weedkiller judgment; FDA approves first birth-control app to be marketed as contraception method; Regulators okay landmark RNAi-based therapy.
The first non-opioid opioid-withdrawal treatment, Lucemyra, hit the market this week.
FDA approves record number of generics in July; Trump drug-pricing policies may be hurting generic makers; Justice Department joins opioid lawsuit.
The point-of-care healthcare marketing company also conducted an initial study with Nielsen on its audience.
Rite Aid, Albertsons call off merger; AMA disapproves of CVS-Aetna deal; FDA signs off on first generic drug for CGT designation.
The partnership will give Kyne a presence in Mexico, Argentina, and Colombia.
Trump promises move to lower drug prices; CVS, Novo Nordisk beat earnings predictions; AstraZeneca settles two suits with Texas for $110 million.
Alderman is reporting to Varsha Rao, Clover's COO